Get the Stockscreener App
2.20
2.22%
-0.05
Iovance Biotherapeutics Inc stock is traded at $2.20, with a volume of 10.59M.
It is down -2.22% in the last 24 hours and down -13.39% over the past month.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
See More
Previous Close:
$2.25
Open:
$2.24
24h Volume:
10.59M
Relative Volume:
0.79
Market Cap:
$873.33M
Revenue:
$241.53M
Net Income/Loss:
$-389.92M
P/E Ratio:
-1.7886
EPS:
-1.23
Net Cash Flow:
$-323.54M
1W Performance:
+0.00%
1M Performance:
-13.39%
6M Performance:
-4.76%
1Y Performance:
-72.36%
1-Day Range:
$2.17
$2.26
1-Week Range:
$2.16
$2.34
52-Week Range:
$1.6385
$8.15
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Name
Iovance Biotherapeutics Inc
Sector
Industry
Phone
(650) 260-7120
Address
825 INDUSTRIAL ROAD, SAN CARLOS
Compare IOVA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
2.20 | 893.18M | 241.53M | -389.92M | -323.54M | -1.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-15-25 | Downgrade | Goldman | Neutral → Sell |
| May-16-25 | Downgrade | UBS | Buy → Neutral |
| May-12-25 | Downgrade | Truist | Buy → Hold |
| May-09-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Oct-24-24 | Initiated | UBS | Buy |
| Jul-29-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-20-23 | Initiated | Goldman | Buy |
| Sep-18-23 | Reiterated | Barclays | Overweight |
| May-30-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-27-23 | Resumed | Wells Fargo | Equal Weight |
| Jan-27-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-09-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-31-22 | Initiated | Guggenheim | Neutral |
| Aug-18-22 | Resumed | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Stifel | Hold → Buy |
| Dec-07-21 | Resumed | Cowen | Outperform |
| Jun-10-21 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| May-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-19-21 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| May-19-21 | Downgrade | Stifel | Buy → Hold |
| May-03-21 | Initiated | Truist | Buy |
| Apr-16-21 | Initiated | Goldman | Buy |
| Mar-08-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-15-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-06-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-22-20 | Initiated | Mizuho | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Feb-26-20 | Reiterated | H.C. Wainwright | Buy |
| Feb-26-20 | Reiterated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | JMP Securities | Mkt Outperform |
| Oct-01-19 | Initiated | Stifel | Buy |
| Apr-29-19 | Initiated | Piper Jaffray | Overweight |
| Feb-28-19 | Reiterated | Chardan Capital Markets | Buy |
| Feb-07-19 | Initiated | Robert W. Baird | Outperform |
| Dec-31-18 | Resumed | B. Riley FBR | Buy |
| Jul-06-18 | Reiterated | Chardan Capital Markets | Buy |
| Apr-10-18 | Upgrade | B. Riley FBR, Inc. | Neutral → Buy |
| Mar-13-18 | Reiterated | B. Riley FBR, Inc. | Neutral |
| Feb-23-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Jan-25-18 | Reiterated | H.C. Wainwright | Buy |
| Nov-01-17 | Reiterated | B. Riley FBR, Inc. | Buy |
View All
Iovance Biotherapeutics Inc Stock (IOVA) Latest News
What analysts say about Iovance Biotherapeutics Inc 2LB stockLong-Term Investment Plans & Advanced Stock Screening Tools - earlytimes.in
Iovance Biotherapeutics Stock: Analyzing Its Surprising Surge - StocksToTrade
Will Iovance Biotherapeutics’ Stock Surge? - timothysykes.com
Iovance Biotherapeutics: A Surge or A Signal to Watch? - timothysykes.com
Iovance Biotherapeutics (IOVA): Is the Market Overlooking a Potential Rebound in Valuation After a Tough Year? - Yahoo Finance
Weighing Iovance Biotherapeutics After a 71.8% Slide and DCF Upside in 2025 - Yahoo Finance
With Iovance Biotherapeutics Stock Sliding, Have You Assessed The Risk? - Trefis
2 Stocks That Could Soar by 52% and 282%, According to Wall Street - Finviz
2 Stocks That Could Soar by 52% and 282%, According to Wall Street - The Motley Fool
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA), MBX Biosciences, Inc. (MBX) and Praxis Precision Medicines (PRAX) - The Globe and Mail
What earnings margins imply for Iovance Biotherapeutics Inc. (2LB) stockWeekly Stock Analysis & Fast Momentum Stock Entry Tips - Newser
Why Iovance Biotherapeutics Inc. (2LB) stock benefits from AI revolutionJuly 2025 PostEarnings & Safe Capital Investment Plans - Newser
What technical charts say about Iovance Biotherapeutics Inc. stock2025 Price Action Summary & Reliable Entry Point Trade Alerts - Newser
Will Iovance Biotherapeutics Inc. stock recover faster than peersWeekly Stock Summary & Verified Entry Point Signals - Newser
How buyback programs support Iovance Biotherapeutics Inc. (2LB) stockInsider Selling & Free Verified High Yield Trade Plans - Newser
Why Iovance Biotherapeutics Inc. (2LB) stock is upgraded to buyMarket Activity Recap & Daily Technical Forecast Reports - Newser
What dividend safety rating applies to Iovance Biotherapeutics Inc. (2LB) stock2025 Earnings Surprises & Weekly Return Optimization Alerts - Newser
Cash per share of Iovance Biotherapeutics Inc – DUS:2LB - TradingView
Why Iovance Biotherapeutics Inc. (2LB) stock is listed among top recommendationsChart Signals & Community Trade Idea Sharing Platform - Newser
Is Iovance Biotherapeutics Inc. (2LB) stock ideal for retirement investors2025 Fundamental Recap & Precise Trade Entry Recommendations - Newser
Officer Graf Finckenstein Acquires 6,247 Of Iovance Biotherapeutics Inc [IOVA] - TradingView
Officer Puri Acquires 3,002 Of Iovance Biotherapeutics Inc [IOVA] - TradingView
Iovance Biotherapeutics (NASDAQ: IOVA) officer reports RSU vesting and tax withholding on Form 4 - Stock Titan
Why Iovance Biotherapeutics Inc. stock remains undervaluedJuly 2025 Closing Moves & Free Low Drawdown Momentum Trade Ideas - Newser
Iovance Biotherapeutics Stock Hits Day Low of $2 Amid Price Pressure - Markets Mojo
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Down 7.9%What's Next? - MarketBeat
FINAL REMINDER IOVA DEADLINE: Bronstein, Gewirtz & Grossman LLC A - The National Law Review
Class Action Lawsuit Filed: Iovance Biotherapeutics, Inc. (IOVA)Join by July 14, 2025Contact Levi & Korsinsky - The National Law Review
Iovance Biotherapeutics Stock Dips Amid Market Reactions - StocksToTrade
Virtus Investment Advisers LLC Increases Position in Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
Commercial Lessons From The Cell And Gene Therapy Frontlines - Citeline News & Insights
Class Action Lawsuit Filed Against Iovance Biotherapeutics, Inc - The National Law Review
IOVA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Iovance Biotherapeutics, Inc. (IOVA) Class Action Lawsuit: Levi - The National Law Review
Kennondale Capital Management LLC Invests $384,000 in Iovance Biotherapeutics, Inc. $IOVA - MarketBeat
Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - 富途牛牛
Iovance’s Tumultuous Journey: Positive Drug Trials Amidst Financial Turbulence - StocksToTrade
Iovance Biotherapeutics: Several Positives, But Competition Still Threatens (NASDAQ:IOVA) - Seeking Alpha
Barclays Boosts IOVA Price Target to $9, Maintains Overweight Ra - GuruFocus
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Is Iovance Biotherapeutics Inc. stock gaining market shareWall Street Watch & Risk Managed Investment Signals - newser.com
Why Iovance Biotherapeutics Inc. (2LB) stock remains stable2025 Performance Recap & Free Technical Confirmation Trade Alerts - newser.com
Why Iovance Biotherapeutics Inc. (2LB) stock gets analyst attentionJuly 2025 Market Mood & Precise Entry and Exit Recommendations - newser.com
What technical patterns form on Iovance Biotherapeutics Inc. (2LB) stock charts - newser.com
How Iovance Biotherapeutics Inc. (2LB) stock compares with market leadersMarket Movement Recap & AI Based Buy and Sell Signals - newser.com
Quantitative breakdown of Iovance Biotherapeutics Inc. recent moveGlobal Markets & High Accuracy Swing Entry Alerts - newser.com
Iovance Biotherapeutics Inc Stock (IOVA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):